Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lean fecal microbiota capsules
- Development stage
- Unknown
- Lead developer
- Vrije University Medical Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lean fecal microbiota capsules are an investigational microbiome-based therapeutic developed by Amsterdam UMC. The product consists of fecal microbiota harvested from healthy, lean donors and processed into oral capsules for delivery. It is designed to treat metabolic disorders, including metabolic syndrome, obesity, and type 2 diabetes, by correcting gut dysbiosis and restoring a microbial profile associated with metabolic health. The therapeutic rationale is based on clinical evidence suggesting that fecal microbiota transplantation (FMT) from lean donors can improve insulin sensitivity and glucose metabolism in recipients with metabolic syndrome. It is currently being evaluated in the RESET trial.
- Other names
- encapsulated fecal microbiota transplantationlean donor FMT capsules
02
Targets
Multidrug-resistant or dysbiotic intestinal taxa
Beyond the preview
Go deeper on lean fecal microbiota capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lean fecal microbiota capsules.